Half-year report · HY
9776.TEDINET S100X0DA
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥10.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥380m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥338m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥390m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥708m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥343m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥389m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥344m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥251m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥464m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥222m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥256m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥226m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥16.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥16.4bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.1bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥5.1bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥11.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.1bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥3.3bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.4bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥716m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥731m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥407m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥584m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥173m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥526m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥398m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥80.4 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.35 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥70.87 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 67.9% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.3% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥51m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥43m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥8m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | ¥31m |
| Clinical Testing Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥153m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.8bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥404m |
| Medical Devices And Maintenance Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥840m |
| Medical Devices And Maintenance Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥505m |
| Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥335m |
| Medical Devices And Maintenance Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥2m |
| —segment total | revenue | 2025-04-01 → 2025-09-30 | ¥10.5bn |
| —segment total | revenue external | 2025-04-01 → 2025-09-30 | ¥10.2bn |
| —segment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥335m |
| —segment total | segment profit | 2025-04-01 → 2025-09-30 | ¥558m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥10.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥10.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥343m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥590m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥58m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | ¥37m |
| Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.9bn |
| Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥158m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.6bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥352m |
| Medical Devices And Maintenance Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥800m |
| Medical Devices And Maintenance Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥426m |
| Medical Devices And Maintenance Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| Medical Devices And Maintenance Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥2m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.3bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥9.9bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥375m |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥507m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥10.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥379m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥545m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 533
| Item | Context | Value | Unit |
|---|---|---|---|
| Revenues from external customers | InterimDuration_jpcrp040300-ssr_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 504950000 | JPY |
| Revenues from external customers | InterimDuration_ReportableSegmentsMember | 10194970000 | JPY |
| Revenues from external customers | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 43098000 | JPY |
| Revenues from external customers | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 10238068000 | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E04950-000ClinicalTestingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | InterimDuration_jpcrp040300-ssr_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 335069000 | JPY |
| Transactions with other segments | InterimDuration_ReportableSegmentsMember | 335069000 | JPY |
| Transactions with other segments | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 7721000 | JPY |
| Transactions with other segments | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 342791000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 3923512000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 5766507000 | JPY |
| Net sales | InterimDuration_jpcrp040300-ssr_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 840019000 | JPY |
| Net sales | InterimDuration_ReportableSegmentsMember | 10530039000 | JPY |
| Net sales | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 50820000 | JPY |
| Net sales | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 10580860000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E04950-000ClinicalTestingBusinessReportableSegmentsMember | 153092000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E04950-000DispensingPharmacyBusinessReportableSegmentsMember | 403620000 | JPY |
| Operating income | InterimDuration_jpcrp040300-ssr_E04950-000MedicalDevicesAndMaintenanceBusinessReportableSegmentsMember | 1739000 | JPY |
| Operating income | InterimDuration_ReportableSegmentsMember | 558451000 | JPY |
| Operating income | InterimDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 31077000 | JPY |
| Operating income | InterimDuration_TotalOfReportableSegmentsAndOthersMember | 589528000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)北海道財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-11-10 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第62期中（自 2025年４月１日 至 2025年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)札幌臨床検査センター株式会社 | |
| Company name in english cover page | FilingDateInstant | SAPPORO CLINICAL LABORATORY INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 伊達 忠應 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北三条西十八丁目２番地２ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | ０１１（６１３）３２１０ | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)総務部長 南 誠 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北三条西十八丁目２番地２ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０１１（６１３）３２１０ | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)総務部長 南 誠 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E04950 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 97760 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)札幌臨床検査センター株式会社 | |
| Filer name in english | FilingDateInstant | SAPPORO CLINICAL LABORATORY INC. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |